Detalhe da pesquisa
1.
Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Respiration
; 92(2): 98-106, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27544537
2.
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.
Lung Cancer (Auckl)
; 8: 217-229, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158696
3.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
J Clin Oncol
; 35(35): 3924-3933, 2017 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023213
4.
Clinical perspectives on pulmonary systemic and macromolecular delivery.
Adv Drug Deliv Rev
; 58(9-10): 996-1008, 2006 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-16996638
5.
Treatment of severe advanced emphysema with volume reduction using lung sealant: a case report of 2 patients.
J Bronchology Interv Pulmonol
; 20(1): 58-62, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23328146
6.
MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
Lung Cancer
; 76(3): 373-9, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22236866
7.
Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
J Clin Oncol
; 28(6): 942-8, 2010 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20100967